◀ Return to Press Releases

Benvenue Medical Secures $64 Million Financing

Spine Company is Well-Poised for Rapid Growth in Vertebral Compression Fracture and Degenerative Disc Disease Markets

 

Santa Clara, Calif., June 16, 2014Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced it completed a $64 million round of financing. The spine company intends to use the proceeds to build its US commercial presence, scale up manufacturing, increase administrative functions to support overall corporate growth and provide working capital to fund growth in operating activities.

The financing is a combination of $40 million in Series E equity supplemented with $24 million in debt.  The Series E equity financing was led by new investor InterWest Partners with all existing major investors participating and Silicon Valley Bank was the sole debt provider.  “We welcome new investor InterWest Partners, and we’re gratified by the continued support from our existing investors and Silicon Valley Bank, who has been our long-standing banking partner.  We believe the large investment in our company is due to Kiva’s successful U.S. launch, the Luna device bearing a CE mark and its upcoming FDA submission. We’re all very excited about the enthusiastic response we’ve received from the spine community,” commented Robert Weigle, CEO of Benvenue Medical.

Benvenue also welcomes Gil Kliman, M.D. from InterWest Partners to its Board of Directors.  “Benvenue Medical is, without a doubt, one of the most exciting companies in the spine category.  We’re happy to be a part of the significant positive momentum that clearly shows how well- positioned the company is for considerable commercial success in the global spine market,” said Dr. Kliman.

“Silicon Valley Bank is very pleased to showcase our on-going strong partnership with Benvenue, who is poised to bring clinically proven technology to patients and physicians in the spine market,” said Jason Hughes, Managing Director with Silicon Valley Bank’s Northern California Life Sciences group.

Benvenue Medical has entered a $9 billion global spine device market with its three minimally invasive products to treat degenerative disc disease (DDD) with spinal fusion and vertebral compression fractures (VCFs):

  • Kiva® VCF Treatment System provides a new implant-based approach to vertebral augmentation in the treatment of painful VCFs.  Kiva was recently launched in the U.S. and it is commercially available in Europe. Kiva has been shown, in at least three comparative studies with a total of more than 500 patients, to meet or exceed the performance of balloon kyphoplasty, the standard of care. Kiva is indicated for the reduction and treatment of spine fractures in the thoracic and/or lumbar spine from T6-L5. It is intended to be used in combination with the Benvenue Vertebral Augmentation Cement Kit.
  • Blazer®- C Vertebral Augmentation System is used by physicians to create channels within the vertebral body for bone cement delivery. The Blazer-C System is indicated for the treatment of pathological compression fractures of the vertebral body that may result from osteoporosis, benign lesions, malignant lesions, by creating channels in the existing spinal bone structure for the flow of polymethylmethacrylate bone cement (PMMA).
  • Luna® Interbody System is used in minimally invasive spinal fusion procedures for degenerative disc disease and incorporates Benvenue Medical’s proprietary implant technology. It has received the CE Mark. It is not currently available in the U.S.

About Benvenue Medical, Inc.

Founded in 2004, Benvenue Medical, Inc. develops next-generation, minimally invasive expandable implants for the spine. The company is privately held and funded by InterWest Partners, Versant Ventures, DeNovo Ventures, Domain Associates and Technology Partners. Its first products are designed for the treatment of vertebral compression fractures and degenerative disc disease, which have combined revenues of $9 billion globally. For more information, visit www.benvenuemedical.com.

###

ML3588.A

◀ Return to Press Releases

  • Disclaimer

    The Kiva and Blazer Vertebral Augmentation systems are cleared by the FDA for distribution in the United States and bear the CE Mark for distribution in the European Union.
    The Luna 360 Interbody System is pending 510(k) clearance, and is not available for sale in the United States.
    ML3430.D